13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100052936 | 2021-11-10 | 2021-11-06 | The establishment of metabolic fingerprints-aided diagnostic model of neuromyelitis optica spectrum disorder | High-throughput metabolic fingerprints characterize neuromyelitis optica spectrum disorder | Neuromyelitis Optica Spectrum Disorders | Gold Standard:Cell-based assay (CBA) for antibody testing as recommended.;Index test:Matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS) is responsible for the obtainment of biofluid metabolic fingerprints, which is further processed by machine learning algorithm, yielding Receiver Operating Characteristic (ROC) curve and area under curve (AUC) calculated to provide comparison.; | Renji Hospital, School of Medicine, Shanghai Jiao Tong University | NULL | Pending | 18 | 85 | Both | Target condition:76;Difficult condition:13 | N/A | China |
| 2 | ChiCTR2000040363 | 2020-11-23 | 2020-11-28 | Clinical study of cerebrospinal fluid immunoglobulin G oligoclonal band detection in Chinese patients with multiple sclerosis | Clinical study of cerebrospinal fluid immunoglobulin G oligoclonal band detection in Chinese patients with multiple sclerosis | Multiple Sclerosis | Gold Standard:Isoelectric focusing electrophoresis;Index test:(1) CSF IgG index (2) CSF 24-hour intrathecal synthesis rate (3) CSF-OCB testing type (4) CSF-OCB positive rate; | Huashan Hospital, Fudan University | NULL | Recruiting | 14 | 65 | Both | Target condition:180;Difficult condition:90 | N/A | China |
| 3 | ChiCTR2000034098 | 2020-07-01 | 2020-06-23 | A New Quantitative Method Used to Evaluate Cervical Spinal Cord Damage in Multiple Sclerosis: Diffusional Kurtosis Imaging Research | A New Quantitative Method Used to Evaluate Cervical Spinal Cord Damage in Multiple Sclerosis: Diffusional Kurtosis Imaging Research | Multiple Sclerosis | Gold Standard:Conventional cervical MRI;Index test:Diffusional Kurtosis Imaging; | The First Hospital of Jilin University | NULL | Pending | Both | Target condition:48;Difficult condition:0 | China | |||
| 4 | NCT03993171 (ClinicalTrials.gov) | December 19, 2019 | 31/5/2019 | 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis. | A Phase 2, Open-Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Multiple Sclerosis. | Relapsing Remitting Multiple Sclerosis | Drug: gold nanocrystals | Clene Nanomedicine | University of Texas Southwestern Medical Center | Recruiting | 18 Years | 55 Years | All | 30 | Phase 2 | United States |
| 5 | NCT04120675 (ClinicalTrials.gov) | November 9, 2018 | 24/9/2019 | Efficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis | The Effects of Early Harvest Extra Virgin Olive Oil on Cognition and Mental Health of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis Patients | Progressive Multiple Sclerosis | Dietary Supplement: Early Harvest Extra Virgin Olive Oil | Aristotle University Of Thessaloniki | Greek Alzheimer's Association and Related Disorders;Ellis-Farm, Eliama Daily Value Gold (ellis-farm.com) | Completed | 18 Years | 65 Years | All | 30 | N/A | Greece |
| 6 | ChiCTR-DND-17013749 | 2017-12-01 | 2017-12-07 | Application of 3.0 T MRI 3D sequences of CUBE-T2 FLAIR?DIR for brain lesions of childhood-onset multiple sclerosis | Application of 3.0 T MRI 3D sequences of CUBE-T2 FLAIR?DIR for brain lesions of childhood-onset multiple sclerosis | childhood-onset multiple sclerosis | Gold Standard:CUBE-T2 FLAIR scanning;Index test:DIR scanning; | Children's Hospital of Chongqing Medical University | NULL | Recruiting | Both | Target condition:80;Difficult condition:0 | China | |||
| 7 | EUCTR2010-024017-31-IT (EUCTR) | 15/03/2011 | 08/02/2011 | A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy - GOLDEN | A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy - GOLDEN | Relapsing Remitting Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10063399 | Product Name: FINGOLIMOD Product Code: FTY720D Trade Name: EXTAVIA INN or Proposed INN: Interferon beta-1b Trade Name: AVONEX INN or Proposed INN: Interferon beta-1a Trade Name: COPAXONE INN or Proposed INN: Glatiramer acetate | NOVARTIS FARMA | NULL | Not Recruiting | Female: yes Male: yes | Italy |